Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience AB has updated its dividend policy following the formation of a new Board of Directors. The revised policy focuses on developing the company’s project portfolio and forming partnerships or selling projects. If significant proceeds are obtained, the Board intends to distribute them to shareholders, aligning the capital structure with long-term strategic goals. This update is part of Alligator’s efforts to enhance its focus on the development and partnering of its lead drug candidate, mitazalimab, ensuring alignment with its strategic priorities.
More about Alligator Bioscience AB
Alligator Bioscience is a clinical-stage biotechnology company specializing in the development of tumor-directed immuno-oncology antibody drugs, primarily targeting the CD40 receptor. This approach aims to enhance the priming of tumor-specific T cells and counteract the immunosuppressive tumor microenvironment, offering potential benefits for cancer patients. The company’s lead drug candidate, mitazalimab, is advancing towards Phase 3 development following promising results in metastatic pancreatic cancer trials. Alligator Bioscience is listed on Nasdaq Stockholm and is based in Lund, Sweden.
Average Trading Volume: 186,895
Current Market Cap: SEK67.62M
For detailed information about ATORX stock, go to TipRanks’ Stock Analysis page.